Scarica l'app Stockscreener
84.71
0.79%
0.66
Dopo l'orario di chiusura:
84.68
-0.03
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Merck Co Inc Borsa (MRK) Ultime notizie
Leerink Partners Maintained a Buy on Merck & Co (MRK) - uk.finance.yahoo.com
Is Pfizer a Millionaire Maker? - The Motley Fool
Goldman Sachs Slashes PT on Merck & Co. (MRK) to $94 From $99, Keeps a Buy Rating - MSN
Merck Shakes Off Some Claims From Cholesterol Drugs Suit - Law360
Lilly-Merck Combo Drug For Lung Cancer Receives FDA Breakthrough StatusEli Lilly (NYSE:LLY) - Benzinga
Merck Taps US Investment-Grade Bond Market for Verona Purchase - Bloomberg.com
Merck's cholesterol drug gets a boost with another late-stage trial success - Reuters
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK) - Benzinga
Merck's Portfolio and Solid Late-Stage Pipeline Defend Against Upcoming Keytruda Headwinds - Morningstar
Leerink Partners Remains Bullish on Merck & Co. (MRK) - MSN
No Spoils For VICTOR As Bayer/Merck & Co’s Verquvo Fails Phase III Trial - insights.citeline.com
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - PharmiWeb.com
Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate - MarketScreener
Merck succeeds in late-stage trial for cholesterol drug - Seeking Alpha
Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study - Business Wire
Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028 - Yahoo Finance
Merck & Co. Inc. (MRK) Initiates Phase 3 Trial on Breast Cancer Drug - MSN
Animal Health Market Trends, Key Player Strategies, and Growth Outlook to 2034 - GlobeNewswire Inc.
Co. Inc.Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial - Yahoo Finance
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction - FinancialContent
Is Merck Stock Outperforming the Dow? - MSN
Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Merck to Participate in the 2025 Wells Fargo Healthcare Conference - PharmiWeb.com
2025 Wells Fargo Healthcare Conference - Merck.com
Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances - Insider Monkey
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% in Q2 2025 - AInvest
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% - Yahoo Finance
Summit, Akeso Lung Cancer Drug Rivals Merck’s KeytrudaSummit Therapeutics (NASDAQ:SMMT) - Benzinga
Rising as One, Shining as Many - GlobeNewswire Inc.
Merck & Co., Inc. shares fall 1.73% intraday after Bernstein reiterates Neutral rating, lowering target price to EUR 138. - AInvest
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025 - The Globe and Mail
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck shares snapped six-session winning streak (NYSE:MRK) - Seeking Alpha
Merck & Co Inc (MRK) Highlights Gaps in Flea and Tick Prevention Adherence - AInvest
Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal - BioWorld MedTech
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds - Business Wire
Can Keytruda Sustain Merck's Growth Through the Rest of 2025? - Yahoo Finance
Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal - insights.citeline.com
Merck KGaA Signs $2 Billion Neurology Drug Pact With Skyhawk - Bloomberg.com
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target - Seeking Alpha
Q3 EPS Estimates for Merck & Co., Inc. Cut by Zacks Research - Defense World
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - MSN
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial - MSN
Merck Stock: Buy The Weakness (NYSE:MRK) - Seeking Alpha
Austria Accepts Merck Commitments After ‘Predatory Pricing’ Undermined Generics - insights.citeline.com
1.62%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):